SOPHiA GENETICS Revolutionizes Liquid Biopsy Testing with MSK-ACCESS® Adoption
SOPHiA GENETICS has reached a remarkable milestone with the global adoption of its innovative cancer testing applications, MSK-ACCESS® powered by SOPHiA DDM™ and MSK-IMPACT® powered by SOPHiA DDM™. This is especially noteworthy as thirty-seven esteemed healthcare institutions, including significant research centers and thought leaders in oncology, have integrated these groundbreaking liquid biopsy and solid tumor applications into their medical practices.
One of the leading figures in this initiative is Professor Umberto Malapelle, who oversees the Predictive Molecular Pathology Laboratory at the University Federico II in Naples, Italy. As the Scientific Secretary of the International Society of Liquid Biopsy, Professor Malapelle has been a vocal advocate for these applications, underscoring their importance in lung cancer research among other oncological studies. He expressed excitement regarding the collaboration with SOPHiA GENETICS, stating, "I see SOPHiA GENETICS as true collaborators to help pave the way for the future of cancer research."
The urgency of advancing healthcare technologies is not lost on SOPHiA GENETICS. According to Ross Muken, President of the company, partnering with pioneering institutions is vital to enhance healthcare universally. He stated, "We are proud to work with trailblazers like Professor Malapelle, who are utilizing our technology and the collective power of our network to make strides in the next wave of cancer care."
A remarkable feature of the MSK-ACCESS® application is its decentralized testing capabilities. Within just ten months following the launch of the liquid biopsy application, thirty-four institutions have signed on to deploy MSK-ACCESS®. This approach allows hospitals and labs worldwide to conduct liquid biopsy testing in-house, providing patients with a less invasive option for genomic analysis. This decentralized testing approach not only reduces overall costs but also shortens turnaround times for results. Furthermore, it enables medical institutions to maintain control over patient data, which can be critical for ongoing research and future applications.
Several renowned healthcare organizations have adopted the MSK-ACCESS® application, including Heidelberg University Hospital in Germany, Biopticka Laboratory in the Czech Republic, and several major clinical facilities in Spain, France, and Canada. The scope of this project reflects an impressive collaboration among leading cancer research hospitals globally.
In addition, the complementary solid tumor application, MSK-IMPACT® powered by SOPHiA DDM™, has garnered widespread interest from further international organizations, showcasing the comprehensive adoption of SOPHiA's technology across different facets of cancer research. Some prominent institutions in this regard encompass the Jiménez Díaz Foundation University Hospital in Spain and the Cyprus Institute of Neurology and Genetics.
The collaborative journey between Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS dates back to 2023, with a shared vision to leverage the advanced SOPHiA DDM™ technology in enhancing cancer testing capabilities worldwide. The first Liquid Biopsy test, MSK-ACCESS®, powered by SOPHiA DDM™, was launched in April 2024, followed by the announcement of a partnership with AstraZeneca in October 2024 aimed at accelerating the deployment of this breakthrough technology. Moreover, the launch of the complementary Solid Tumor test further demonstrates their commitment to revolutionizing cancer diagnostics and treatment based on robust real-world data and insights from diverse populations.
For those interested in learning more about these advancements in cancer care, SOPHiA GENETICS is hosting a virtual webinar titled 'Precision Oncology Showcase' on February 25, 2025. This event will emphasize the pivotal role of decentralized, AI-driven technologies in the evolution of cancer treatments and patient management.
SOPHiA GENETICS is dedicated to reshaping patient care globally with its cloud-native technology and innovative approaches to data-driven medicine. Through its continuous efforts and partnerships, SOPHiA remains at the forefront of enhancing access to advanced cancer diagnostics, ultimately working towards improved patient outcomes.
One of the leading figures in this initiative is Professor Umberto Malapelle, who oversees the Predictive Molecular Pathology Laboratory at the University Federico II in Naples, Italy. As the Scientific Secretary of the International Society of Liquid Biopsy, Professor Malapelle has been a vocal advocate for these applications, underscoring their importance in lung cancer research among other oncological studies. He expressed excitement regarding the collaboration with SOPHiA GENETICS, stating, "I see SOPHiA GENETICS as true collaborators to help pave the way for the future of cancer research."
The urgency of advancing healthcare technologies is not lost on SOPHiA GENETICS. According to Ross Muken, President of the company, partnering with pioneering institutions is vital to enhance healthcare universally. He stated, "We are proud to work with trailblazers like Professor Malapelle, who are utilizing our technology and the collective power of our network to make strides in the next wave of cancer care."
A remarkable feature of the MSK-ACCESS® application is its decentralized testing capabilities. Within just ten months following the launch of the liquid biopsy application, thirty-four institutions have signed on to deploy MSK-ACCESS®. This approach allows hospitals and labs worldwide to conduct liquid biopsy testing in-house, providing patients with a less invasive option for genomic analysis. This decentralized testing approach not only reduces overall costs but also shortens turnaround times for results. Furthermore, it enables medical institutions to maintain control over patient data, which can be critical for ongoing research and future applications.
Several renowned healthcare organizations have adopted the MSK-ACCESS® application, including Heidelberg University Hospital in Germany, Biopticka Laboratory in the Czech Republic, and several major clinical facilities in Spain, France, and Canada. The scope of this project reflects an impressive collaboration among leading cancer research hospitals globally.
In addition, the complementary solid tumor application, MSK-IMPACT® powered by SOPHiA DDM™, has garnered widespread interest from further international organizations, showcasing the comprehensive adoption of SOPHiA's technology across different facets of cancer research. Some prominent institutions in this regard encompass the Jiménez Díaz Foundation University Hospital in Spain and the Cyprus Institute of Neurology and Genetics.
The collaborative journey between Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS dates back to 2023, with a shared vision to leverage the advanced SOPHiA DDM™ technology in enhancing cancer testing capabilities worldwide. The first Liquid Biopsy test, MSK-ACCESS®, powered by SOPHiA DDM™, was launched in April 2024, followed by the announcement of a partnership with AstraZeneca in October 2024 aimed at accelerating the deployment of this breakthrough technology. Moreover, the launch of the complementary Solid Tumor test further demonstrates their commitment to revolutionizing cancer diagnostics and treatment based on robust real-world data and insights from diverse populations.
For those interested in learning more about these advancements in cancer care, SOPHiA GENETICS is hosting a virtual webinar titled 'Precision Oncology Showcase' on February 25, 2025. This event will emphasize the pivotal role of decentralized, AI-driven technologies in the evolution of cancer treatments and patient management.
SOPHiA GENETICS is dedicated to reshaping patient care globally with its cloud-native technology and innovative approaches to data-driven medicine. Through its continuous efforts and partnerships, SOPHiA remains at the forefront of enhancing access to advanced cancer diagnostics, ultimately working towards improved patient outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.